IN2012DN02577A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02577A
IN2012DN02577A IN2577DEN2012A IN2012DN02577A IN 2012DN02577 A IN2012DN02577 A IN 2012DN02577A IN 2577DEN2012 A IN2577DEN2012 A IN 2577DEN2012A IN 2012DN02577 A IN2012DN02577 A IN 2012DN02577A
Authority
IN
India
Prior art keywords
compounds
jak
pyrrolo
inhibitors
preparation
Prior art date
Application number
Inventor
Brad Alan Acker
Susan J Hartmann
Horng-Chih Huang
Eric Jon Jacobsen
Michele Ann Promo
Sergey Gregory Wolfson
Jin Xie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IN2012DN02577A publication Critical patent/IN2012DN02577A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Described herein are pyrrolo[2,3-d]pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing these compounds, and methods for their preparation.
IN2577DEN2012 2009-10-15 2010-10-01 IN2012DN02577A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25203909P 2009-10-15 2009-10-15
PCT/IB2010/054447 WO2011045702A1 (en) 2009-10-15 2010-10-01 Pyrrolo[2,3-d] pyrimidine compounds

Publications (1)

Publication Number Publication Date
IN2012DN02577A true IN2012DN02577A (en) 2015-08-28

Family

ID=43413616

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2577DEN2012 IN2012DN02577A (en) 2009-10-15 2010-10-01

Country Status (29)

Country Link
US (1) US8633206B2 (en)
EP (1) EP2488524B1 (en)
JP (1) JP5629324B2 (en)
KR (1) KR20120083452A (en)
CN (1) CN102574860A (en)
AP (1) AP2012006192A0 (en)
AR (1) AR078635A1 (en)
AU (1) AU2010308028A1 (en)
CA (1) CA2776028C (en)
CL (1) CL2012000795A1 (en)
CO (1) CO6531451A2 (en)
CR (1) CR20120164A (en)
CU (1) CU20120059A7 (en)
DO (1) DOP2012000080A (en)
EA (1) EA201290147A1 (en)
EC (1) ECSP12011855A (en)
ES (1) ES2426407T3 (en)
IL (1) IL218802A0 (en)
IN (1) IN2012DN02577A (en)
MA (1) MA33670B1 (en)
MX (1) MX2012004379A (en)
NI (1) NI201200053A (en)
PE (1) PE20121077A1 (en)
PH (1) PH12012500583A1 (en)
TN (1) TN2012000146A1 (en)
TW (1) TWI398444B (en)
UY (1) UY32947A (en)
WO (1) WO2011045702A1 (en)
ZA (1) ZA201202718B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
EA023857B1 (en) 2009-03-23 2016-07-29 Гленмарк Фармасеутикалс С.А. Fused pyrimidine-dione derivatives as trpa1 modulators
SG174398A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Furopyrimidinedione derivatives as trpa1 modulators
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRECURSORS AND THEIR METHODS OF USE
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
ES2461967T3 (en) * 2009-12-18 2014-05-21 Pfizer Inc. Pyrrolo [2,3-d] pyrimidine compounds
DK2620428T3 (en) * 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetric help group
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
BR112014002472A2 (en) 2011-08-12 2017-04-11 Nissan Chemical Ind Ltd "tricyclic heterocyclic compounds, their use, therapeutic agent for joint rheumatism and drug"
DK2872485T3 (en) 2012-07-13 2021-03-08 Wave Life Sciences Ltd ASYMMETRIC ASSISTANCE GROUP
JP6246121B2 (en) 2012-07-13 2017-12-13 株式会社新日本科学 Chiral nucleic acid adjuvant
CN112007045B (en) 2012-07-13 2026-01-06 波涛生命科学有限公司 Chiral control
HRP20180061T1 (en) * 2012-07-17 2018-02-23 Glaxosmithkline Intellectual Property (No. 2) Limited INDOLCARBONITRILES AS SELECTIVE MODULATORS OF ANDROGENIC RECEPTORS
CN103896946B (en) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 For preventing and treating the noval chemical compound of various autoimmune disease
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
EP2955181B1 (en) 2013-02-08 2019-10-30 Nissan Chemical Corporation Tricyclic pyrrolopyridine compound, and jak inhibitor
EP3290421B1 (en) * 2013-02-22 2019-01-02 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
KR20160002857A (en) * 2013-05-02 2016-01-08 에프. 호프만-라 로슈 아게 Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
WO2015108048A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR102423317B1 (en) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 Chiral design
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2015174376A1 (en) 2014-05-14 2015-11-19 日産化学工業株式会社 Tricyclic compound and jak inhibitor
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
MX374347B (en) * 2016-02-16 2025-03-06 Zoetis Services Llc PROCESS FOR PREPARING 7H-PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS
CN107098908B (en) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 Preparation method and application of pyrrolopyrimidine compound
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CA3127892A1 (en) 2019-01-30 2020-08-06 Gargamel (Zhuhai) Biotech Ltd. Jak inhibitor and preparation method thereof
IL264854A (en) * 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
CN114025758B (en) * 2019-07-01 2026-05-08 钱立刚 P2X7R antagonist
AU2020338043B2 (en) * 2019-08-26 2025-12-18 Chemwerth, Inc. Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors
JP2022549506A (en) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド Methods for treating myelofibrosis and related conditions
KR20230012539A (en) 2020-05-13 2023-01-26 디스크 메디슨, 인크. Anti-hemojuvelin (HJV) antibodies to treat myelofibrosis
CN115246833B (en) * 2021-04-27 2024-08-13 洛阳惠中兽药有限公司 Preparation method of Olatinib compound and intermediate compound thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
PL198640B1 (en) 1998-06-19 2008-07-31 Pfizer Prod Inc PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
EA006227B1 (en) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. PIRROLO(2,3-d)PYRIMIDINE COMPOUNDS
EA006153B1 (en) * 2000-06-26 2005-10-27 Пфайзер Продактс Инк. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
CN101353321A (en) 2002-11-21 2009-01-28 辉瑞产品公司 3-amino-piperidine derivatives and preparation methods thereof
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
JP2007511596A (en) 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク Pyrrolopyrimidine compounds useful in the treatment of cancer
WO2005085253A1 (en) 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine derivatives
WO2006014325A2 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
AR054416A1 (en) * 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
EP1904457B1 (en) 2005-06-08 2017-09-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN102127078A (en) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Heterocyclic janus kinase 3 inhibitors
CN101233138A (en) 2005-07-29 2008-07-30 辉瑞产品公司 Pyrrolo[2,3-d]pyrimidine derivatives, intermediates and synthetic methods thereof
JP2009513571A (en) 2005-09-30 2009-04-02 バーテックス ファーマシューティカルズ インコーポレイテッド Deazapurine useful as a Janus kinase inhibitor
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
JP2009528295A (en) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Compositions and methods for inhibition of the JAK pathway
MX2008011127A (en) * 2006-03-02 2008-10-31 Astellas Pharma Inc 17β HSD type 5 INHIBITOR.
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009115084A2 (en) 2008-03-20 2009-09-24 Schebo Biotech Ag Novel pyrrolopyrimidine derivatives and the use thereof
HRP20140395T1 (en) * 2008-08-20 2014-06-06 Zoetis Llc PIROLO [2,3-d] PIRIMIDINE COMPOUNDS

Also Published As

Publication number Publication date
ES2426407T3 (en) 2013-10-23
UY32947A (en) 2011-05-31
US8633206B2 (en) 2014-01-21
JP2013508266A (en) 2013-03-07
CA2776028C (en) 2015-12-01
CA2776028A1 (en) 2011-04-21
AU2010308028A1 (en) 2012-04-19
TW201125866A (en) 2011-08-01
JP5629324B2 (en) 2014-11-19
EA201290147A1 (en) 2012-11-30
TN2012000146A1 (en) 2013-09-19
CO6531451A2 (en) 2012-09-28
CR20120164A (en) 2012-11-07
NI201200053A (en) 2012-08-09
IL218802A0 (en) 2012-06-28
CL2012000795A1 (en) 2012-09-07
MX2012004379A (en) 2012-06-01
AR078635A1 (en) 2011-11-23
PE20121077A1 (en) 2012-08-10
CU20120059A7 (en) 2012-06-29
PH12012500583A1 (en) 2012-10-22
EP2488524B1 (en) 2013-07-03
ZA201202718B (en) 2012-12-27
WO2011045702A1 (en) 2011-04-21
US20110136765A1 (en) 2011-06-09
TWI398444B (en) 2013-06-11
EP2488524A1 (en) 2012-08-22
AP2012006192A0 (en) 2012-04-30
KR20120083452A (en) 2012-07-25
ECSP12011855A (en) 2012-06-29
MA33670B1 (en) 2012-10-01
DOP2012000080A (en) 2012-06-15
CN102574860A (en) 2012-07-11

Similar Documents

Publication Publication Date Title
EA201290147A1 (en) PIRROLO [2,3-D] PYRIMIDINE COMPOUNDS
MX2012009074A (en) Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors.
HUS2000006I1 (en) Substituted pyrazolo[1,5-]pyrimidine compounds as trk kinase inhibitors
UY32059A (en) PIRROLO COMPOUNDS [2,3-D] PYRIMIDINE
PH12015501779B1 (en) Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
TN2011000245A1 (en) Organic compounds
SG10201603095TA (en) SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
MX2015010858A (en) Solid forms of a selective cdk4/6 inhibitor.
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
MX2011005935A (en) Organic compounds.
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
AP2010005346A0 (en) 3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as mTOR kinase and P13 kinase inhibitors, and their synthesis.
PH12014500103A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
JO2822B1 (en) kinase INHIBITORS 6s 70AKT AND P
PT2658844T (en) Novel pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX336332B (en) Kinase inhibitors, prodrug forms thereof and their use in therapy.
TW200745102A (en) Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof
CY1115106T1 (en) PYROLOL [2,3-D] PYRIMIDINE COMPOUNDS
HK1170730A (en) Imidazopyridine derivatives as jak inhibitors
HK1172905A (en) Pyrazole derivatives as jak inhibitors